Clinical Trial Update: A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a triplet regimen of pirtobrutinib, venetoclax, and rituximab in Waldenström macroglobulinemia and lymphoplasmacytic lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoplasmacytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Status: RECRUITING